Cargando…
T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges
Despite decades of research, pediatric central nervous system (CNS) tumors remain the most debilitating, difficult to treat, and deadliest cancers. Current therapies, including radiation, chemotherapy, and/or surgery, are unable to cure these diseases and are associated with serious adverse effects...
Autores principales: | Haydar, Dalia, Ibañez-Vega, Jorge, Krenciute, Giedre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573171/ https://www.ncbi.nlm.nih.gov/pubmed/34760690 http://dx.doi.org/10.3389/fonc.2021.718030 |
Ejemplares similares
-
Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
por: Petersen, Christopher T., et al.
Publicado: (2019) -
IMMU-01. Combining CD28 and 4-1BB costimulationin trans enhances the anti-glioma efficacy and persistence of B7-H3 CAR T cells in immune-competent brain tumor models
por: Haydar, Dalia, et al.
Publicado: (2022) -
Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma
por: Williams, Maria J., et al.
Publicado: (2017) -
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
por: Yi, Zhongzhen, et al.
Publicado: (2018) -
Chromatin mutations in pediatric high grade gliomas
por: Voon, Hsiao P. J., et al.
Publicado: (2023)